8-K: AngioDynamics Reports Strong Med Tech Growth and Raises Full Year Profitability Guidance

AngioDynamics announced positive second quarter fiscal year 2025 results, highlighted by a 25% increase in Med Tech sales and raised full year profitability guidance.

Summary

• AngioDynamics reported a 9.2% increase in pro forma net sales to $73.0 million for the second quarter of fiscal year 2025.
• The Med Tech segment saw a significant 25.0% increase in net sales, reaching $31.5 million, driven by strong performance across all product lines.
• Med Device net sales were $41.5 million, a slight decrease of 0.4% compared to the prior year.
• The company achieved a GAAP gross margin of 54.8% and an adjusted EBITDA of $3.1 million.
• AngioDynamics received CPT Category I codes for Irreversible Electroporation (IRE) for prostate and liver lesions, effective January 1, 2026.
• The company also received FDA 510(k) clearance for NanoKnife prostate tissue ablation in December 2024.
• The PRESERVE clinical trial for NanoKnife met all primary endpoints, showing 84% of men were free from clinically significant disease at 12 months.
• Fiscal year 2025 guidance was raised for Adjusted EBITDA to a range of $1.0 to $3.0 million and Adjusted EPS to a loss between $0.34 and $0.38.
• The company generated $2.5 million in operating cash during the quarter and had $54.1 million in cash and cash equivalents at the end of November 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in the Med Tech segment, key regulatory approvals, and improved profitability guidance. While there are some challenges in the Med Device segment and a GAAP loss, the overall tone is optimistic and indicates a positive trajectory for the company.

Positives

• The Med Tech segment demonstrated strong growth, with a 25% increase in sales.
• The company achieved positive Adjusted EBITDA of $3.1 million.
• Operating cash flow was positive at $2.5 million for the quarter.
• The company received important regulatory approvals and CPT codes for NanoKnife, which should improve market access.
• The PRESERVE study results validate the safety and efficacy of the NanoKnife system.
• The company raised its full-year guidance for Adjusted EBITDA and Adjusted EPS, indicating improved profitability expectations.
• The company is making progress on its shift to outsourced manufacturing, which is expected to generate $15 million in annual cost savings by FY 2027.

Negatives

• Med Device net sales decreased slightly by 0.4% year-over-year.
• International net sales decreased by 6.6% compared to the prior year.
• The company recorded a GAAP net loss of $10.7 million, or a loss per share of $0.26.
• Gross margin for the Med Device business decreased by 240 basis points due to inflationary pressures and costs associated with the transition to outsourced manufacturing.
• The company expects to utilize cash in the third fiscal quarter.

Risks

• The company faces risks related to the COVID-19 pandemic, product development, competition, regulatory actions, and economic conditions.
• There are risks associated with ongoing litigation, third-party distributors, and product recalls.
• The company's ability to execute strategic initiatives and integrate acquired businesses is subject to risk.
• The company is exposed to risks from foreign currency exchange rate fluctuations and pricing pressures from group purchasing organizations.
• The transition to outsourced manufacturing may present challenges and could impact gross margins in the short term.

Future Outlook

AngioDynamics raised its fiscal year 2025 guidance for Adjusted EBITDA to a range of $1.0 to $3.0 million and Adjusted EPS to a loss between $0.34 and $0.38. The company expects to utilize cash in the third fiscal quarter and generate cash in the fourth fiscal quarter. Full market release of Auryon in Europe is expected in the first quarter of calendar 2025.

Management Comments

• Jim Clemmer, President and Chief Executive Officer, stated that the company is very excited about its strong performance during the second quarter, particularly the continued strength of the Med Tech segment.
• He also noted that the company hit a number of key milestones for the NanoKnife System, with the receipt of CPT Category I Codes and FDA 510(k) clearance for prostate tissue ablation.
• He commented that these achievements put the company in a fantastic position to drive accelerated growth for NanoKnife in coming quarters.
• He also stated that through a combination of strong sales results, increasing contribution from the Med Tech segment, and operating efficiency efforts, the company delivered positive Adjusted EBITDA and operating cash flow in the quarter.

Industry Context

The medical technology industry is seeing increased demand for minimally invasive procedures, which aligns with AngioDynamics' focus on technologies like NanoKnife. The company's success in obtaining CPT codes and FDA clearance for its prostate ablation technology positions it well in the competitive landscape. The growth in the Med Tech segment reflects a broader trend towards advanced medical devices and therapies.

Comparison to Industry Standards

• AngioDynamics' 25% growth in Med Tech sales is strong compared to the overall medical device industry, which typically sees single-digit growth.
• Companies like Boston Scientific and Medtronic, which also operate in the medical device space, have reported varying growth rates in their respective segments, but AngioDynamics' Med Tech growth is notable.
• The successful completion of the PRESERVE study and the subsequent FDA clearance for NanoKnife in prostate tissue ablation is a significant achievement, placing AngioDynamics in a competitive position against other prostate cancer treatment options.
• The company's focus on minimally invasive procedures aligns with industry trends and patient preferences, potentially giving it an edge over companies offering more invasive treatments.
• The shift to outsourced manufacturing is a common strategy in the medical device industry to reduce costs and improve efficiency, and AngioDynamics' expected $15 million in annual cost savings is a significant benefit.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and increased profitability guidance.
• Employees may see increased job security and potential for growth due to the company's positive trajectory.
• Customers, including physicians and hospitals, will have access to innovative medical technologies.
• Patients will benefit from the availability of minimally invasive treatment options, particularly for prostate cancer.
• Suppliers and creditors may see increased business opportunities due to the company's growth.

Next Steps

• The company will continue to expand the commercial launch of NanoKnife for prostate tissue ablation.
• The company will execute a full commercial launch of the AlphaVac PE indication in the U.S. and CE Marked countries.
• The company will continue to increase penetration of Auryon in the hospital setting in the U.S.
• The company will conduct a limited market release of Auryon in Europe before transitioning to a full market release in the first quarter of calendar 2025.
• The company will launch new products to refine and enhance usability of its existing product lines.

Key Dates

Keywords

AngioDynamics, Med Tech, Med Device, NanoKnife, Auryon, AngioVac, AlphaVac, Irreversible Electroporation, CPT Codes, FDA Clearance, Prostate Cancer, Thrombectomy, EBITDA, Financial Results